Enasidenib is a targeted drug for relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutations.Purchase Channels for EnasidenibOverseas Purchase(1) Patients may choose to visit hospital pha...
Enasidenib is a targeted drug indicated for relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation, and its trade name is IDHIFA. Given its specific indications and prescription-only n...